Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended April 30, 1999.
Business Overview: The Company operates two primary segments: CooperVision (CVI), which markets contact lenses (specializing in toric lenses for astigmatism), and CooperSurgical (CSI), which markets diagnostic products and surgical instruments for women's healthcare. The Company also recently divested its psychiatric services business, Hospital Group of America (HGA).
Key Financial Metrics
Revenue (Six Months Ended April 30, 1999): $76.7 million (up 15% from $66.8 million in 1998).
Net Income: $11.0 million (down from $14.5 million in 1998, largely due to the absence of prior-year tax benefits and discontinued operations adjustments).
Income from Continuing Operations: $7.9 million (down from $12.7 million in 1998).
Earnings Per Share (Diluted): $0.77 for the six months ended April 30, 1999 (vs. $0.94 in 1998).
Gross Margin: 63% for the six months ended April 30, 1999 (down from 64% in 1998).
Operating Cash Flow: $5.8 million provided by operating activities for the six months ended April 30, 1999 (vs. $3.8 million used in 1998).
Debt: Total debt reduced to $63.0 million (down from $90.3 million at Oct 31, 1998).
Liquidity: Cash and cash equivalents stood at $5.4 million as of April 30, 1999. The Company has $25.4 million available under its KeyBank line of credit.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by CooperVision (CVI), which grew 17% year-to-date, fueled by the acquisition of Aspect Vision Care and strong sales of toric lenses. CooperSurgical (CSI) revenue grew 5%.
- Discontinued Operations: The Company sold the remainder of HGA in April 1999, recording a gain on disposal of $1.7 million in the quarter and $3.1 million for the six months. This contrasts with the $22.3 million charge recorded in fiscal 1998.
- Tax Provision: The effective tax rate for the six months ended April 30, 1999, was approximately 34%. This reflects a shift from the prior year, where the Company recorded significant tax benefits from reversing valuation allowances on net operating loss carryforwards.
- Debt Reduction: Proceeds from the HGA sale were used to pay down debt, reducing total debt by approximately $27.3 million and lowering the debt-to-equity ratio from 0.6:1 to 0.4:1.
- Share Repurchases: The Company completed its authorized repurchase of 1 million shares of common stock, spending a total of $15.3 million.
Guidance, Outlook, and Risks
Outlook: Management expects cash flow from continuing operations to be sufficient to fund ongoing operations and pay cash dividends. An annual cash dividend of 8 cents per share was declared, with the first payment scheduled for July 5, 1999. The Company anticipates continued margin improvement in the second half of fiscal 1999 as integration of Aspect Vision completes and cost reduction projects mature.
Risks and Contingencies:
- Year 2000 (Y2K): The Company is implementing a compliance program with final testing expected by July 31, 1999. Estimated total cost is $500,000. While no material problems are anticipated, risks remain regarding third-party vendors and undetected system issues.
- Environmental: Groundwater contamination (trichloroethane) was identified at a CVI site. The Company has accrued $500,000 for remediation and entered a voluntary cleanup agreement with the New York DEC. Management does not expect costs to be material beyond current accruals.
- Market Risk: Exposure to foreign exchange (primarily Pound Sterling) and interest rate fluctuations. The Company utilizes hedging contracts and interest rate swaps to mitigate these risks.
Investor Verification Checklist
- Verify the sustainability of CooperVision's revenue growth post-Aspect acquisition integration.
- Confirm the actual effective tax rate for the full fiscal year 1999 against the projected 34%.
- Monitor the progress and final costs of the Y2K compliance program and the environmental remediation at the CVI site.
- Assess the impact of the new dividend policy on future cash flow and capital allocation for potential acquisitions.
- Review the performance of new product launches at CooperSurgical (CSI) to ensure continued margin expansion.